Updated:
Hyperfine
Jonathan Rothberg founded Hyperfine in 2014 to deploy portable, FDA-cleared MRI technology that brings brain imaging to the patient bedside.
Hyperfine
Rothberg founded Hyperfine, Inc. in 2014 as one of several ventures emerging from his Guilford, Connecticut-based 4Catalyzer medtech incubator, a model that previously produced Butterfly Network and the DNA-sequencing company Ion Torrent. The firm's first commercial product, the Swoop Portable MR Imaging System, pursued an unusual regulatory path — securing FDA 510(k) clearance first for head imaging in 2020 and later expanding its indications. The Swoop system targets point-of-care brain imaging for stroke diagnosis, hydrocephalus assessment, and other acute neurological conditions with a device that rolls to the patient and plugs into a standard wall outlet. Strategy centers on disrupting the centralized MRI business model by placing low-field, low-cost scanners in emergency departments and intensive-care beds, not just in radiology suites. Deployment spans the United States, with devices installed in academic medical centers and rural community hospitals alike, including Yale New Haven Health and Penn Medicine. Hyperfine operates as a publicly traded entity through a 2021 SPAC combination with HealthCor Catalio Acquisition Corp, trading under the symbol HYPR. The firm shares corporate infrastructure and executive overlap with Rothberg's broader 4Catalyzer portfolio, creating a lean operational footprint that routes R&D through a centralized team of engineers and scientists. A published multi-site study in 2022 demonstrated the Swoop system's ability to detect acute stroke in emergency settings at 85 sites across the U.S. and Europe, an unusually broad clinical evidence push for an early-stage device company. Rothberg's founder-investor model — incubate, de-risk, and take public — differs from venture-backed medtech orthodoxy by keeping technical leadership inside a tight network of serial inventors rather than outsourcing core science to a transplanted management team. For allocators, the architecture matters: Hyperfine's capital efficiency is tied to a shared-services incubator that carries multiple companies under one roof, a structure few pure-play diagnostics firms match.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Guilford
Corporate office
Guilford, CT, United States
Principals
Jonathan Rothberg
Founder
Sector focus
Frequently asked questions
How is Hyperfine's technology structurally different from a traditional MRI system?
Hyperfine builds low-field, portable MRI scanners that operate at 0.064 Tesla, roughly 20–25 times weaker than conventional hospital MRI magnets. The Swoop unit is wheeled, plugs into a standard electrical outlet, and requires no cryogenic cooling or shielded room — engineering choices that remove the infrastructure barriers of superconducting systems. This unbundling allows imaging at the point of care, not just in centralized radiology departments.
What is the relationship between Hyperfine and Jonathan Rothberg's 4Catalyzer incubator?
Hyperfine was founded within the 4Catalyzer incubator in Guilford, Connecticut, and shares R&D, engineering talent, and corporate infrastructure with other Rothberg-founded companies. The incubator model allows portfolio ventures to access cross-disciplinary scientific teams without each startup building its own full-stack organization from scratch. 4Catalyzer previously incubated Butterfly Network, which brought semiconductor-based ultrasound to market through the same shared-resource thesis.
Does Hyperfine sell its devices or operate a service model?
Hyperfine sells the Swoop system as a capital equipment purchase to hospitals and health systems, with recurring revenue from software subscriptions and service agreements. The firm has also explored leasing and per-scan pricing arrangements at select sites. The installed base spans both large academic medical centers and smaller community hospitals where on-call MRI technologist coverage may be unavailable after hours.
Who runs investment decisions at Hyperfine?
Hyperfine is a publicly traded, medical-device operating company listed on Nasdaq (HYPR); it is not a family office or investment fund. Capital allocation decisions — R&D prioritization, manufacturing scale-up, and commercial spending — are made by management under board governance. The board includes representatives from the SPAC sponsor and Rothberg's affiliated entities, maintaining tight founder alignment.
Which clinical conditions does Hyperfine's technology target first?
The initial FDA-cleared indication covers brain imaging for patients of all ages, with clinical studies focused on acute ischemic stroke detection, hemorrhagic stroke, hydrocephalus, and traumatic brain injury. The low-field, open architecture makes the system particularly suited for bedside scanning of patients too unstable for transport to a conventional MRI suite — a workflow that directly informs the ICU and ED deployment strategy.
How does Hyperfine generate evidence for clinical adoption?
The firm pursues an unusually direct clinical-evidence strategy for an early-stage medtech company, sponsoring multi-site studies that enroll hundreds of patients. A 2022 study published in a peer-reviewed journal evaluated stroke detection across 85 sites in the U.S. and Europe, while ongoing trials target pediatric brain imaging and longitudinal monitoring of neurodegenerative conditions. The evidence push is part of a reimbursement and guideline-inclusion pathway that differs from a lean-regulatory-only approach.
Is Hyperfine a single-family office or a venture firm?
Neither. Hyperfine is a publicly traded medical-device company that designs, manufactures, and sells portable MRI systems. Its relationship with Jonathan Rothberg's 4Catalyzer incubator means it originated within a founder-controlled innovation network, but it operates as a standalone entity with independent governance and Nasdaq listing. Allocators encountering Hyperfine in a portfolio typically hold it as a public equity position rather than a private investment.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: